NORTHERN TRUST CORP - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$11,086,417
-17.4%
244,248
+2.1%
0.00%
-33.3%
Q2 2023$13,426,612
+49.3%
239,163
+20.3%
0.00%
+50.0%
Q1 2023$8,995,072
+17.3%
198,874
+5.4%
0.00%0.0%
Q4 2022$7,668,297
-41.0%
188,642
-5.1%
0.00%
-33.3%
Q3 2022$12,990,000
+16.0%
198,764
+7.9%
0.00%
+50.0%
Q2 2022$11,195,000
+7.7%
184,231
+11.2%
0.00%0.0%
Q1 2022$10,395,000
+216.7%
165,610
+282.4%
0.00%
+100.0%
Q4 2021$3,282,000
-30.7%
43,308
+2.4%
0.00%0.0%
Q3 2021$4,735,000
-44.3%
42,301
-19.4%
0.00%0.0%
Q2 2021$8,497,000
+16.5%
52,481
-12.3%
0.00%0.0%
Q1 2021$7,295,000
-0.6%
59,875
+25.0%
0.00%0.0%
Q4 2020$7,336,000
+93.2%
47,913
+5.5%
0.00%0.0%
Q3 2020$3,798,000
+29.0%
45,413
+13.3%
0.00%0.0%
Q2 2020$2,945,000
+92.4%
40,069
+11.0%
0.00%
Q1 2020$1,531,000
-26.2%
36,093
+6.0%
0.00%
Q4 2019$2,074,000
+59.5%
34,054
+7.3%
0.00%
Q3 2019$1,300,000
-11.1%
31,733
+2.1%
0.00%
Q2 2019$1,463,000
+41.6%
31,078
+7.6%
0.00%
Q1 2019$1,033,000
+62.9%
28,890
+30.1%
0.00%
Q4 2018$634,000
-49.5%
22,207
-21.6%
0.00%
Q3 2018$1,255,000
-11.4%
28,317
+17.4%
0.00%
Q2 2018$1,417,000
+95.2%
24,121
+51.9%
0.00%
Q1 2018$726,00015,8800.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2022
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$32,581,00055.55%
NEA Management Company, LLC 1,590,002$103,907,0005.19%
ARK Investment Management 8,237,122$538,296,0003.75%
Nikko Asset Management Americas, Inc. 4,262,736$277,078,0003.54%
CLOUGH CAPITAL PARTNERS L P 414,767$27,105,0002.89%
Integral Health Asset Management, LLC 220,000$14,377,0002.79%
PLUSTICK MANAGEMENT LLC 50,000$3,268,0002.48%
HC Advisors, LLC 53,944$3,525,0002.43%
Green Alpha Advisors, LLC 27,466$1,795,0001.52%
EFG Asset Management (North America) Corp. 84,356$5,516,0001.28%
View complete list of CRISPR THERAPEUTICS AG shareholders